Lymph node dissection in uterine leiomyosarcomas: A matched-pair study

Gynecol Oncol. 2023 Jul:174:28-33. doi: 10.1016/j.ygyno.2023.04.007. Epub 2023 May 3.

Abstract

Objective: To assess the impact of the lymph node dissection (LND) in the disease-free (DFS) and overall survival (OS) of the women treated surgically of uterine leiomyosarcoma (ULMS).

Material and methods: A multicentric retrospective study was conducted among European countries collecting patients diagnosed of uterine sarcoma (SARcoma of the UTerus - SARCUT study). A total of 390 ULMS were selected for the present study to compare patients who underwent LND and those who did not. A further matched-pair subanalysis identified 116 women, 58 pairs (58 with LND and 58 without it) comparable in age, tumor size, surgical procedures, extrauterine disease and adjuvant treatment. Demographic data, pathology results and follow-up were abstracted from medical records and analyzed. Disease-free (DFS) and overall survival (OS) were studied using Kaplan-Meier curves and Cox regression analysis.

Results: Among the 390 patients, the 5-year DFS was significantly higher in no-LDN group comparing to the LDN group (57.7% vs. 33.0%; HR 1.75, 95% CI 1.19-2.56; p = 0.007), but not the 5-year OS (64.6% vs. 64.3%; HR 1,10 95% CI 0,77-1,79; p = 0.704). In the matched-pair subanalysis, there were no statistical differences between the study groups. The 5- year DFS was 50.5% in the no-LND and 33.0% in the LND group (HR 1.38; 95% CI 0,83-2.31; p = 0,218) and the 5-year OS was 59.7% and 64.3% respectively (HR 0.81; 95% CI 0,45-1,49; p = 0,509).

Conclusions: LND performed in women diagnosed of ULMS have no impact neither in the disease-free nor in the overall survival compared to patients without LDN in a complete homogeneous group.

Keywords: Leiomyosarcoma; Lymph node dissection; Lymphadenectomy; Survival; Uterine sarcoma.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Leiomyosarcoma* / mortality
  • Leiomyosarcoma* / pathology
  • Leiomyosarcoma* / surgery
  • Leiomyosarcoma* / therapy
  • Lymph Node Excision*
  • Lymph Nodes / pathology
  • Lymph Nodes / surgery
  • Lymphatic Metastasis / pathology
  • Lymphatic Metastasis / therapy
  • Middle Aged
  • Proportional Hazards Models
  • Retrospective Studies
  • Uterine Neoplasms* / mortality
  • Uterine Neoplasms* / pathology
  • Uterine Neoplasms* / surgery
  • Uterine Neoplasms* / therapy